Recurrent GBM safety
Optune patients experienced fewer systemic AEs vs
|Incidence of grade 2-4 AEs occurring in ≥5%
|General Deterioration and Malaise||5||6|
|Metabolism and Nutrition Disorders||4||6|
|Nervous system disorders||30||28|
The most common (≥10%) AEs seen with Optune monotherapy were medical device site reaction and headache3
The following AEs were considered related to Optune: medical device site reaction, headache, malaise, muscle twitching, fall, and skin ulcer4
In EF-11, 16% of patients experienced a grade 1/2 medical device reaction2
Mild-to-moderate skin irritation, the most common device-related side effect with Optune, was easily manageable, reversible, and did not result in treatment discontinuation1
Improved safety vs chemotherapy1
Significantly fewer of the systemic AEs associated with chemotherapy, including gastrointestinal side effects, hematological side effects, and infections, were observed with Optune
AE, adverse event; GBM, glioblastoma.
References: 1. Optune Instructions For Use. Novocure 2016. 2. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202. 3. Novocure Data on File OPT-109. 4. Novocure Data on File OPT-110.